文献速递胃肠动力与功能性疾病

肠易激综合征黏膜5-羟色胺再摄取转运体表达受肠道菌群经肥大细胞-前列腺素E2通路调控

Mucosal Serotonin Reuptake Transporter Expression in Irritable Bowel Syndrome Is Modulated by Gut Microbiota Via Mast Cell-Prostaglandin E2.
PubMed 文献 · Gastroenterology · 2022-02-12

研究探讨肠易激综合征(IBS)中黏膜5-羟色胺再摄取转运体(SERT)是否经肠道菌群-肥大细胞-前列腺素E2(PGE2)通路调控。小鼠结肠内灌注腹泻型IBS(IBS-D)患者粪上清液后黏膜5-HT升高、SERT表达降低约50%,该效应依赖肥大细胞、环氧合酶-2和PGE2受体,并可被脂多糖拮抗剂、细菌胰蛋白酶抑制剂及昂丹司琼预防。

要点

  • IBS-D粪上清液使小鼠黏膜5-HT升高、SERT表达降低约50%。
  • SERT下调依赖肥大细胞、环氧合酶-2和PGE2受体。
  • 脂多糖拮抗剂、细菌胰蛋白酶抑制剂及昂丹司琼可预防上述改变。

核心结论

  • IBS-D患者粪便中的脂多糖与胰蛋白酶协同刺激黏膜肥大细胞释放PGE2,下调黏膜SERT,导致黏膜5-HT升高,可能参与IBS腹泻和腹痛。

研究设计与样本

  • C57Bl/6小鼠接受健康对照或IBS-D患者粪上清液结肠内灌注,并在肥大细胞缺陷小鼠中研究肥大细胞作用。
  • 使用结肠类器官和/或肥大细胞进行体外实验。
  • SERT表达采用定量聚合酶链反应和蛋白质印迹检测,并评估结直肠扩张内脏运动反应和结肠传输。

主要发现

  • 小鼠结肠内灌注IBS-D粪上清液较健康对照粪上清液引起黏膜5-HT升高,伴SERT表达降低约50%。
  • 肥大细胞稳定剂、环氧合酶-2抑制剂和PGE2受体拮抗剂预防SERT下调。
  • IBS-D粪上清液在肥大细胞缺陷(W/Wv)小鼠中未能降低SERT表达,肥大细胞重建后该反应恢复。
  • IBS粪上清液引起的SERT下调可被球形红细菌脂多糖拮抗剂和细菌胰蛋白酶抑制剂预防。
  • 体外脂多糖处理使培养小鼠肥大细胞环氧合酶-2表达和PGE2释放增加;小鼠结肠内灌注IBS-D粪上清液降低结肠传输、增加粪便含水量并增强结直肠扩张内脏运动反应,昂丹司琼预防这些改变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Increased colonic serotonin (5-HT) level and decreased serotonin reuptake transporter (SERT) expression in irritable bowel syndrome (IBS) may contribute to diarrhea and visceral hypersensitivity. We investigated whether mucosal SERT is modulated by gut microbiota via a mast cell-prostaglandin E2 (PGE2) pathway. METHODS: C57Bl/6 mice received intracolonic infusion of fecal supernatant (FS) from healthy controls or patients with diarrhea-predominant irritable bowel syndrome (IBS-D). The role of mast cells was studied in mast cell-deficient mice. Colonic organoids and/or mast cells were used for in vitro experiments. SERT expression was measured by quantitative polymerase chain reaction and Western blot. Visceromotor responses to colorectal distension and colonic transit were assessed. RESULTS: Intracolonic infusion of IBS-D FS in mice caused an increase in mucosal 5-HT compared with healthy control FS, accompanied by ∼50% reduction in SERT expression. Mast cell stabilizers, cyclooxygenase-2 inhibitors, and PGE2 receptor antagonist prevented SERT downregulation. Intracolonic infusion of IBS-D FS failed to reduce SERT expression in mast cell-deficient (W/Wv) mice. This response was restored by mast cell reconstitution. The downregulation of SERT expression evoked by IBS FS was prevented by lipopolysaccharide (LPS) antagonist LPS from Rhodobacter sphaeroides and a bacterial trypsin inhibitor. In vitro LPS treatment caused increased cyclooxygenase-2 expression and PGE2 release from cultured mouse mast cells. Intracolonic infusion of IBS-D FS in mice reduced colonic transit, increased fecal water content, and increased visceromotor responses to colorectal distension. Ondansetron prevented these changes. CONCLUSIONS: Fecal LPS acting in concert with trypsin in patients with IBS-D stimulates mucosal mast cells to release PGE2, which downregulates mucosal SERT, resulting in increased mucosal 5-HT. This may contribute to diarrhea and abdominal pain common in IBS.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Gao J, Xiong T, Grabauskas G, et al. Mucosal Serotonin Reuptake Transporter Expression in Irritable Bowel Syndrome Is Modulated by Gut Microbiota Via Mast Cell-Prostaglandin E2. Gastroenterology. 2022. PMID: 35167867. doi:10.1053/j.gastro.2022.02.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。